Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.

Ferrari A, Baraldi C, Licata M, Vandelli D, Marchesi F, Palazzoli F, Verri P, Rustichelli C, Giuliani E, Silingardi E.

Eur J Clin Pharmacol. 2016 Sep;72(9):1075-81. doi: 10.1007/s00228-016-2074-5. Epub 2016 May 31.

2.

The optimal management of headaches in children and adolescents.

Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL.

Ther Adv Neurol Disord. 2016 Jan;9(1):53-68. doi: 10.1177/1756285615616586. Review.

3.

Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.

Ferrari LF, Levine JD, Green PG.

Neuroscience. 2016 Mar 11;317:121-9. doi: 10.1016/j.neuroscience.2016.01.005. Epub 2016 Jan 11.

PMID:
26779834
4.

The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.

Reuter U, Israel H, Neeb L.

Ther Adv Neurol Disord. 2015 Jan;8(1):46-54. doi: 10.1177/1756285614562419. Review.

5.

Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.

Savi L, Mogavero S, Egan CG.

Drug Des Devel Ther. 2014 Jul 21;8:983-92. doi: 10.2147/DDDT.S61295. eCollection 2014.

6.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

Bell IM, Gallicchio SN, Wood MR, Quigley AG, Stump CA, Zartman CB, Fay JF, Li CC, Lynch JJ, Moore EL, Mosser SD, Prueksaritanont T, Regan CP, Roller S, Salvatore CA, Kane SA, Vacca JP, Selnick HG.

ACS Med Chem Lett. 2010 Jan 12;1(1):24-9. doi: 10.1021/ml900016y. eCollection 2010 Apr 8.

7.

The complex actions of sumatriptan on rat dural afferents.

Harriott AM, Scheff NN, Gold MS.

Cephalalgia. 2012 Jul;32(10):738-49. doi: 10.1177/0333102412451356. Epub 2012 Jun 18.

8.

Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres.

Baillie LD, Ahn AH, Mulligan SJ.

Neuropharmacology. 2012 Sep;63(3):362-7. doi: 10.1016/j.neuropharm.2012.04.016.

9.

The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.

Tfelt-Hansen PC, Olesen J.

J Headache Pain. 2012 Jun;13(4):271-5. doi: 10.1007/s10194-012-0428-7. Epub 2012 Mar 20. Review.

10.

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache.

Moore JC, Miner JR.

Patient Prefer Adherence. 2012;6:27-37. doi: 10.2147/PPA.S19171. Epub 2012 Jan 4.

11.

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Johnson MW, Sewell RA, Griffiths RR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):132-40. doi: 10.1016/j.drugalcdep.2011.10.029. Epub 2011 Nov 29.

12.

Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?

Mitsikostas DD, Knight YE, Lasalandra M, Kavantzas N, Goadsby PJ.

J Headache Pain. 2011 Aug;12(4):411-7. doi: 10.1007/s10194-011-0352-2. Epub 2011 May 29.

13.

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.

Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B.

J Headache Pain. 2011 Jun;12(3):361-8. doi: 10.1007/s10194-011-0325-5. Epub 2011 Mar 25.

14.
15.

Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Balaban CD, Jacob RG, Furman JM.

Expert Rev Neurother. 2011 Mar;11(3):379-94. doi: 10.1586/ern.11.19.

16.

Are the current IHS guidelines for migraine drug trials being followed?

Hougaard A, Tfelt-Hansen P.

J Headache Pain. 2010 Dec;11(6):457-68. doi: 10.1007/s10194-010-0257-5. Epub 2010 Oct 8. Review.

17.

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.

Ferrari A, Tiraferri I, Neri L, Sternieri E.

J Headache Pain. 2011 Feb;12(1):5-12. doi: 10.1007/s10194-010-0258-4. Epub 2010 Sep 29. Review.

18.

A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine.

Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D, Pinessi L.

J Headache Pain. 2011 Apr;12(2):219-26. doi: 10.1007/s10194-010-0243-y. Epub 2010 Aug 5.

19.

Verisimilitude (or "truthlikeness") as an alternative to pro and cons: migraine and cluster headache mechanisms.

Tfelt-Hansen PC.

J Headache Pain. 2010 Oct;11(5):379-89. doi: 10.1007/s10194-010-0232-1. Epub 2010 Jul 7. Review.

20.

Distribution of 5-HT1B and 5-HT1D receptors in the inner ear.

Ahn SK, Balaban CD.

Brain Res. 2010 Jul 30;1346:92-101. doi: 10.1016/j.brainres.2010.05.057. Epub 2010 May 26.

Items per page

Supplemental Content

Write to the Help Desk